ATE182581T1 - Metalloproteinase-inhibitoren - Google Patents
Metalloproteinase-inhibitorenInfo
- Publication number
- ATE182581T1 ATE182581T1 AT95922639T AT95922639T ATE182581T1 AT E182581 T1 ATE182581 T1 AT E182581T1 AT 95922639 T AT95922639 T AT 95922639T AT 95922639 T AT95922639 T AT 95922639T AT E182581 T1 ATE182581 T1 AT E182581T1
- Authority
- AT
- Austria
- Prior art keywords
- metalloproteinase inhibitors
- compounds
- inhibitors
- medicine
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9412514A GB9412514D0 (en) | 1994-06-22 | 1994-06-22 | Metalloproteinase inhibitors |
GBGB9506107.3A GB9506107D0 (en) | 1995-03-24 | 1995-03-24 | Metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE182581T1 true ATE182581T1 (de) | 1999-08-15 |
Family
ID=26305102
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95922639T ATE182581T1 (de) | 1994-06-22 | 1995-06-22 | Metalloproteinase-inhibitoren |
AT95922638T ATE191468T1 (de) | 1994-06-22 | 1995-06-22 | Metalloproteinase inhibitoren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95922638T ATE191468T1 (de) | 1994-06-22 | 1995-06-22 | Metalloproteinase inhibitoren |
Country Status (17)
Country | Link |
---|---|
US (4) | US5962529A (de) |
EP (2) | EP0766665B1 (de) |
JP (2) | JPH10507158A (de) |
CN (1) | CN1151157A (de) |
AT (2) | ATE182581T1 (de) |
AU (2) | AU695507B2 (de) |
CA (2) | CA2193692A1 (de) |
DE (2) | DE69516143T2 (de) |
DK (2) | DK0766665T3 (de) |
ES (2) | ES2133785T3 (de) |
FI (1) | FI965153A (de) |
GB (2) | GB2303850B (de) |
GR (2) | GR3031143T3 (de) |
NO (1) | NO965515L (de) |
NZ (2) | NZ288299A (de) |
PT (1) | PT766664E (de) |
WO (2) | WO1995035275A1 (de) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US6380366B1 (en) * | 1994-04-28 | 2002-04-30 | Les Laboratoires Aeterna Inc. | Shark cartilage extract:process of making, methods of using and compositions thereof |
US5962529A (en) * | 1994-06-22 | 1999-10-05 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
KR980009238A (ko) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
DE69624536T2 (de) * | 1995-08-08 | 2003-06-05 | Ono Pharmaceutical Co | Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase |
TR199800849T2 (xx) † | 1995-11-13 | 1998-07-21 | Hoechst Aktiengesellschaft | Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
EP1095936B1 (de) * | 1995-12-08 | 2004-11-24 | Agouron Pharmaceuticals, Inc. | Zwischenprodukte zur Herstellung von Metallproteinasehemmern |
TW453995B (en) * | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
BR9707010B1 (pt) * | 1996-01-23 | 2009-05-05 | compostos, composição farmacêutica e composições para inibir metaloproteinase e colagenase do tipo iv. | |
US5994351A (en) * | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE69707865T2 (de) * | 1996-05-17 | 2002-05-02 | Warner Lambert Co | Biphenylsulfonamid matrix metalloproteinase inhibitoren |
WO1998006711A1 (en) * | 1996-08-16 | 1998-02-19 | Warner-Lambert Company | Butyric acid matrix metalloproteinase inhibitors |
WO1998007697A1 (en) * | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
IL128667A (en) * | 1996-08-28 | 2002-04-21 | Procter & Gamble | Spirocyclic metroprotease inhibitors and pharmaceutical preparations containing them |
IL128664A (en) * | 1996-08-28 | 2003-07-06 | Procter & Gamble | Heterocyclic metalloprotease inhibitors and pharmaceutical compositions comprising them |
BR9712792A (pt) * | 1996-08-28 | 1999-12-14 | Procter & Gamble | Inibidores de metaloprotease bidentada. |
PL331838A1 (en) * | 1996-08-28 | 1999-08-02 | Procter & Gamble | 1,3-diheterocyclic inhibitors of metaloproteases |
DK0925303T3 (da) * | 1996-08-28 | 2003-02-24 | Procter & Gamble | Phosphinsyreamider som matrixmetalloproteaseinhibitorer |
WO1998008827A1 (en) * | 1996-08-28 | 1998-03-05 | The Procter & Gamble Company | Heterocyclic metalloprotease inhibitors |
PT938471E (pt) * | 1996-10-16 | 2002-05-31 | American Cyanamid Co | A preparacao e uso de acidos ortosulfonamidoarilhidroxamicos como inibidores de metaloproteinases de matriz e "tace" |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
DE69710204T2 (de) * | 1996-10-22 | 2002-10-24 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
AU5426398A (en) | 1996-10-28 | 1998-05-22 | Versicor Inc | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
CN1243507A (zh) * | 1997-01-17 | 2000-02-02 | 法玛西雅厄普约翰美国公司 | 用作mmp抑制剂的双磺酰胺异羟肟酸类化合物 |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6197791B1 (en) | 1997-02-27 | 2001-03-06 | American Cyanamid Company | N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
DK0977745T3 (da) * | 1997-03-04 | 2005-03-14 | Pharmacia Corp | Thioarylsulfonamidhydroxamsyreforbindelser |
GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
JP2001521504A (ja) * | 1997-04-01 | 2001-11-06 | アグロン・ファーマシュウティカルズ・インコーポレーテッド | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用 |
US5756545A (en) * | 1997-04-21 | 1998-05-26 | Warner-Lambert Company | Biphenysulfonamide matrix metal alloproteinase inhibitors |
DE59802394D1 (de) * | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
WO1998050348A1 (en) * | 1997-05-09 | 1998-11-12 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
US6300514B1 (en) | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
ID29293A (id) | 1997-07-22 | 1999-01-28 | Shionogi & Co | KOMPOSISI UNTUK MENGOBATI ATAU MENCEGAH GLOMERULOPATI (Pecahan dari No. W20000054) |
NZ503945A (en) | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
EP0895988B1 (de) * | 1997-08-08 | 2002-05-22 | Pfizer Products Inc. | Arylsulfonylaminohydroxamsäurederivate |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
GB9801690D0 (en) * | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
WO1999042436A1 (en) * | 1998-02-19 | 1999-08-26 | American Cyanamid Company | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
GB9810464D0 (en) | 1998-05-16 | 1998-07-15 | British Biotech Pharm | Hydroxamic acid derivatives |
CN1194978C (zh) | 1998-07-16 | 2005-03-30 | 阿文蒂斯药物德国有限公司 | 用作药物的次膦酸和膦酸衍生物 |
US6107337A (en) * | 1998-08-06 | 2000-08-22 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
CN1178915C (zh) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途 |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6506936B1 (en) * | 1999-02-25 | 2003-01-14 | Fibrogen, Inc. | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production |
EP1165501A1 (de) | 1999-03-03 | 2002-01-02 | The Procter & Gamble Company | Alkenyl- und alkinylhaltige metalloproteasehemmer |
EP1165530A2 (de) | 1999-03-03 | 2002-01-02 | The Procter & Gamble Company | Dihetero-substituierte metalloprotease-inhibitoren |
PT1041072E (pt) | 1999-03-31 | 2003-11-28 | Pfizer Prod Inc | Acidos dioxociclopentil hidroxamicos |
WO2001017995A1 (en) | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
CA2389681C (en) | 1999-11-26 | 2010-11-02 | Shionogi & Co., Ltd. | Npy y5 antagonist |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
KR20030005229A (ko) * | 2000-03-21 | 2003-01-17 | 더 프록터 앤드 갬블 캄파니 | 메탈로프로테아제 저해제를 함유하는 탄소환식 측쇄 |
EP1265863A1 (de) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Metalloprotease-inhibitoren mit einer heterocyklischen seitenkette |
CZ20023145A3 (cs) * | 2000-03-21 | 2003-01-15 | The Procter And Gamble Company | Heterocyklický postranní řetězec obsahující N-substituované inhibitory metaloproteas a farmaceutický přípravek s jejich obsahem |
CA2401728A1 (en) * | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
US6495358B1 (en) | 2000-04-19 | 2002-12-17 | Wichita State University | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes |
AU2001265182A1 (en) | 2000-05-30 | 2001-12-11 | Rafael Fridman | Inhibitors of matrix metalloproteinases |
AU2002256672A1 (en) * | 2001-03-14 | 2002-09-24 | Novartis Ag | Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
WO2002092553A1 (en) * | 2001-05-11 | 2002-11-21 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
JP2004535437A (ja) | 2001-06-22 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
AU2003233154A1 (en) | 2002-06-10 | 2003-12-22 | Pfizer Inc. | Metabolites of prinomastat and their sythesis |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
AU2003300379A1 (en) * | 2002-12-27 | 2004-07-29 | Angiotech Pharmaceuticals, Inc. | Compositions and methods of using collagen and MMPI |
DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
US7928127B2 (en) | 2005-05-19 | 2011-04-19 | Notre Dame University | Inhibitors of matrix metallaproteinases |
JP2011528013A (ja) * | 2008-07-14 | 2011-11-10 | ノバルティス アーゲー | ヒドロキサム酸系の選択的mmp−12およびmmp−13阻害剤 |
US8937151B2 (en) | 2010-03-04 | 2015-01-20 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
KR20140045287A (ko) | 2010-09-24 | 2014-04-16 | 랜박시 래보러터리스 리미티드 | 기질 메탈로프로테나제 저해제 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4885027A (en) * | 1985-04-05 | 1989-12-05 | Chevron Research Company | Herbicidal arylmethylenesulfonamido-acetamide and thioacetamide derivatives |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
HUT56050A (en) * | 1987-12-18 | 1991-07-29 | Schering Corp | Process for resolving 2-amino-4phenyl-butane |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
KR927003520A (ko) * | 1990-12-03 | 1992-12-18 | 죤 에드워드 베리만 | 펩티딜(peptidyl) 유도체 |
US5239113A (en) * | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5962529A (en) * | 1994-06-22 | 1999-10-05 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
DE69707865T2 (de) * | 1996-05-17 | 2002-05-02 | Warner Lambert Co | Biphenylsulfonamid matrix metalloproteinase inhibitoren |
-
1995
- 1995-06-22 US US08/765,140 patent/US5962529A/en not_active Expired - Fee Related
- 1995-06-22 AU AU27465/95A patent/AU695507B2/en not_active Ceased
- 1995-06-22 DK DK95922639T patent/DK0766665T3/da active
- 1995-06-22 AT AT95922639T patent/ATE182581T1/de not_active IP Right Cessation
- 1995-06-22 JP JP8501848A patent/JPH10507158A/ja not_active Withdrawn
- 1995-06-22 AT AT95922638T patent/ATE191468T1/de not_active IP Right Cessation
- 1995-06-22 DE DE69516143T patent/DE69516143T2/de not_active Expired - Fee Related
- 1995-06-22 AU AU27466/95A patent/AU690703B2/en not_active Ceased
- 1995-06-22 CA CA002193692A patent/CA2193692A1/en not_active Abandoned
- 1995-06-22 GB GB9623675A patent/GB2303850B/en not_active Expired - Fee Related
- 1995-06-22 NZ NZ288299A patent/NZ288299A/en unknown
- 1995-06-22 ES ES95922639T patent/ES2133785T3/es not_active Expired - Lifetime
- 1995-06-22 CA CA002193691A patent/CA2193691A1/en not_active Abandoned
- 1995-06-22 WO PCT/GB1995/001464 patent/WO1995035275A1/en active IP Right Grant
- 1995-06-22 DK DK95922638T patent/DK0766664T3/da active
- 1995-06-22 ES ES95922638T patent/ES2145913T3/es not_active Expired - Lifetime
- 1995-06-22 PT PT95922638T patent/PT766664E/pt unknown
- 1995-06-22 CN CN95193714A patent/CN1151157A/zh active Pending
- 1995-06-22 US US08/765,146 patent/US6022898A/en not_active Expired - Fee Related
- 1995-06-22 DE DE69511089T patent/DE69511089T2/de not_active Expired - Fee Related
- 1995-06-22 EP EP95922639A patent/EP0766665B1/de not_active Expired - Lifetime
- 1995-06-22 EP EP95922638A patent/EP0766664B1/de not_active Expired - Lifetime
- 1995-06-22 GB GB9623809A patent/GB2303629B/en not_active Expired - Fee Related
- 1995-06-22 NZ NZ288298A patent/NZ288298A/xx unknown
- 1995-06-22 WO PCT/GB1995/001465 patent/WO1995035276A1/en active IP Right Grant
- 1995-06-22 JP JP8501847A patent/JPH10501806A/ja active Pending
-
1996
- 1996-12-20 FI FI965153A patent/FI965153A/fi unknown
- 1996-12-20 NO NO965515A patent/NO965515L/no unknown
-
1999
- 1999-02-03 US US09/243,130 patent/US6124332A/en not_active Expired - Fee Related
- 1999-06-30 US US09/343,087 patent/US6124329A/en not_active Expired - Fee Related
- 1999-09-02 GR GR990402229T patent/GR3031143T3/el unknown
-
2000
- 2000-05-18 GR GR20000401133T patent/GR3033446T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69516143D1 (de) | Metalloproteinase inhibitoren | |
SE9402431D0 (sv) | New tablet formulation | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
ATE253359T1 (de) | Antithrombotische mittel | |
TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. | |
ATE286395T1 (de) | Antithrombotische mittel | |
FI932654A (fi) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
HUP0203321A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrug készítmények gyulladás kezelésére | |
ES2194899T3 (es) | Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido. | |
TR200003451T2 (tr) | Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları | |
DE69910787D1 (de) | Neuartige, pharmazeutisch aktive verbindung | |
NO20001846L (no) | Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer | |
ATE268768T1 (de) | Antithrombosemittel | |
ATE109981T1 (de) | Therapeutische mittel. | |
JO1881B1 (en) | Formula II for multi unit disc calibration | |
IT1255678B (it) | Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale. | |
MX9503130A (es) | Inhibidores de metaloproteinasa, proceso para su preparacion y composiciones farmaceuticas o veterinarias que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REN | Ceased due to non-payment of the annual fee |